checkAd
    Startseite > Aktien > Verve Therapeutics > Nachrichten
    Verve Therapeutics Aktie
    6,3600
     
    USD
    +4,61 %
    +0,2800 USD
    Letzter Kurs 09.05.24 Nasdaq
    6,3600
     
    USD
    1.200 STK
    Geldkurs 09.05.24
    6,3700
     
    USD
    4.300 STK
    Briefkurs 09.05.24
    ISIN: US92539P1012 · WKN: A3CSHT · SYM: VERV · USA

    Neueste Nachrichten

    Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
    08.05.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
    07.05.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    03.05.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Updates on its PCSK9 Program
    02.04.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    28.03.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    01.03.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
    27.02.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    01.02.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    02.01.24 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
    29.11.23 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
    28.11.23 · globenewswire · Verve Therapeutics
    Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
    12.11.23 · globenewswire · Verve Therapeutics